{"type":"trials","record":{"id":29340,"source_id":"clinicaltrials-gov","external_id":"NCT04823260","title":"To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults","brief_summary":"It will be a two-part study. Part I will be six arms; randomized, double blind, parallel design, placebo-controlled dose ranging study. Part II will be open-label single dose study at the highest dose. A total of 90 Subjects (Part 1 \\& Part 2) will be enrolled in the study. The Part 1 group subjects (80 Subjects) shall be randomly distributed between the six arms, i.e. 20 Subjects each in IP arms, and 7, 7 and 6 subjects in corresponding placebo arms. All Part 2 Group subjects (10 Subjects) will be assigned into the cluster where all receive the maximum NMN dose (900 mg)","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Abinopharm, Inc","enrollment":90,"countries":["India"],"start_date":"2021-05-25","completion_date":"2021-09-09","last_update_date":"2021-10-01","source_url":"https://clinicaltrials.gov/study/NCT04823260","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:08.862442+00:00","last_seen_at":"2026-09-25T06:15:13.984+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"40 Years to 65 Years","comparator":"Arm A = 300 mg NMN supplement (n = 20); Arm B = Placebo 300 mg (n=07); Arm C = NMN Supplement 600 mg (n= 20); Arm D = Placebo 600 mg (n=07); Arm E = NMN Supplement 900 mg (n=10); Arm F = Placebo 900 mg (n=06)","organization":"Abinopharm, Inc","interventions":["Nicotinamide Mononucleotide","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Blood cellular NAD+/ NADH — Baseline","Blood cellular NAD+/ NADH — 1 month","Blood cellular NAD+/ NADH — 2 month","Six walking endurance test — Baseline","Six walking endurance test — 1 month","Six walking endurance test — 2 month","SF-36 questionnaire — Baseline","SF-36 questionnaire — 1 month","SF-36 questionnaire — 2 month","PART II : Telomerase test results — Baseline","PART II : Telomerase test results — 2 Months","PART II : SF-36 questionnaire — Baseline","PART II : SF-36 questionnaire — 2 months","safety of NMN — Baseline","safety of NMN — 2 Months","Tolerability of NMN — Baseline","Tolerability of NMN — 2 months","Safety of the different NMN doses — 2 Months","Tolerability different NMN doses — Baseline","Tolerability different NMN doses — 2 Months"],"design_description":"RANDOMIZED · PARALLEL · OTHER · QUADRUPLE","source_has_results":false},"controlled_terms":["Aging","Nicotinamide Mononucleotide","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: nmn.","quality_checked_at":"2026-09-25T06:15:15.562724+00:00","duplicate_cluster_key":"id:nct04823260","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-05-25 to 2021-09-09","comparator":"Arm A = 300 mg NMN supplement (n = 20); Arm B = Placebo 300 mg (n=07); Arm C = NMN Supplement 600 mg (n= 20); Arm D = Placebo 600 mg (n=07); Arm E = NMN Supplement 900 mg (n=10); Arm F = Placebo 900 mg (n=06)","confidence":"structured-source","population":"ALL · 40 Years to 65 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:14.009Z","intervention":["Nicotinamide Mononucleotide","Placebo"],"participants":90,"study_design":"RANDOMIZED · PARALLEL · OTHER · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Blood cellular NAD+/ NADH — Baseline","Blood cellular NAD+/ NADH — 1 month","Blood cellular NAD+/ NADH — 2 month","Six walking endurance test — Baseline","Six walking endurance test — 1 month","Six walking endurance test — 2 month","SF-36 questionnaire — Baseline","SF-36 questionnaire — 1 month","SF-36 questionnaire — 2 month","PART II : Telomerase test results — Baseline","PART II : Telomerase test results — 2 Months","PART II : SF-36 questionnaire — Baseline","PART II : SF-36 questionnaire — 2 months","safety of NMN — Baseline","safety of NMN — 2 Months","Tolerability of NMN — Baseline","Tolerability of NMN — 2 months","Safety of the different NMN doses — 2 Months","Tolerability different NMN doses — Baseline","Tolerability different NMN doses — 2 Months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"nad-metabolism","is_published":true,"match_reasons":["Title contains controlled term: nmn.","Abstract contains controlled term: nmn.","Source terminology contains: nicotinamide mononucleotide.","Title supplies longevity context: ageing.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"NAD metabolism","slug":"nad-metabolism"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/29340","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}